Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2025-02-14 Major Shareholding Noti…
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-01-15 English
Regulatory Filings 2024
Regulatory Filings
2024-12-20 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from Channel Therapeutics Corporation to the SEC regarding a Post-Effective Amendment No. 3 to a Registration Statement on Form S-1. It discusses responses to SEC staff comments and mentions filing an updated legal opinion as an exhibit to a subsequent amendment. The document is short (2848 characters) and primarily serves as a regulatory communication about amendments to a registration statement, not the registration statement itself or a financial report. It does not contain financial data or detailed report content but is a regulatory filing correspondence. Therefore, it fits best under Regulatory Filings (RNS).
2024-12-11 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is titled 'Post-Effective Amendment No. 4 to Form S-1 Registration Statement' filed with the SEC. It references the Securities Act of 1933 and is related to a registration statement for securities. The text includes details about the registrant, legal counsel, and signatures of officers and directors. It also mentions incorporation by reference of various SEC filings such as Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, but this document itself is an amendment to a registration statement, not a financial report or earnings release. The document length is 8926 characters, which is substantial but the content is focused on updating a registration statement, specifically a post-effective amendment to Form S-1. Form S-1 is used for securities registration, and amendments to it are classified under Capital/Financing Update (CAP) as they relate to fundraising and securities registration activities. Therefore, the correct classification is Capital/Financing Update (CAP).
2024-12-11 English
Regulatory Filings 2024
Regulatory Filings
2024-12-05 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.